RFReginald F. Frye

Reginald F. Frye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Reginald F. Frye has a total of 497 co-authors. Here are the top co-authors by number of shared publications:

  • Gary R. Matzke

    College of Pharmacy, Virginia Commonwealth University, Richmond, Virginia

    14 shared publications
  • Robert A. Branch

    Center for Clinical Pharmacology, University of Pittsburgh, Pennsylvania

    10 shared publications
  • Yan Gong

    Department of Pharmacotherapy and Translational Research University of Florida College of Pharmacy, University of Florida Gainesville Florida USA

    9 shared publications
  • Amber L. Beitelshees

    Department of Medicine, University of Maryland, Baltimore, MD

    7 shared publications
  • Julie A. Johnson

    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida Gainesville Florida USA

    7 shared publications
  • Julie A. Johnson

    Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine University of Florida College of Pharmacy Gainesville Florida USA

    7 shared publications

Latest Publications

  • Projecting financial sustainability for clinical pharmacy services: An implementation science brief report

    by Ashley W. Ellis, Cori C. Grant, Christopher K. Finch, Reginald F. Frye, Todd D. Sorensen


  • Open Access

    Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants

    by Fernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, Reginald Frye, Eddison Godinez Leiva, Kenneth Cusi


  • Open Access

    The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects

    by John S. Markowitz, Ludmila De Faria, Qingchen Zhang, Philip W. Melchert, Reginald F. Frye, Brandon O. Klee, Yuli Qian

    Introduction: Cannabidiol (CBD) is a widely utilized nonpsychoactive cannabinoid available as an over-the-counter supplement, a component of medical cannabis, and a prescriptive treatment of childhood epilepsies. In vitro studies suggest CBD may inhibit a number of drug-metabolizing enzymes, including carboxylesterase 1 (CES1). The aim of this study was to evaluate effect of CBD on the disposition of the CES1 substrate methylphenidate (MPH). Methods: In a randomized, placebo-controlled, crossover study, 12 subjects ingested 750 mg of CBD solution, or alternatively, a placebo solution twice daily for a 3-day run-in period followed by an additional CBD dose (or placebo) and a single 10 mg dose of MPH and completed serial blood sampling for pharmacokinetic analysis. MPH and CBD concentrations were measured by liquid chromatography with tandem mass spectrometry. Results: The Cmax (mean ± CV) for the CBD group and placebo group was 13.5 ± 43.7% ng/mL and 12.2 ± 36.4% ng/mL, respectively. AUCinf (ng/mL*h) for the CBD group and placebo group was 70.7 ± 32.5% and 63.6 ± 25.4%, respectively. The CBD AUC0-8h (mean ± CV) was 1,542.2 ± 32% ng/mL*h, and Cmax was 389.2 ± 39% ng/mL. When compared to MPH only, the geometric mean ratio (CBD/control, 90% CI) for AUCinf and Cmax with CBD co-administration was 1.09 (0.89, 1.32) and 1.08 (0.85, 1.37), respectively. Discussion/Conclusion: Although the upper bound of bioequivalence was not met, the mean estimates of AUC and Cmax ratios were generally small and unlikely to be of clinical significance.


  • Open Access

    A randomized, cross‐over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence

    by Scott A. Mosley, Sarah Kim, Nihal El Rouby, Karthik Lingineni, Valvanera Vozmediano Esteban, Yan Gong, Yiqing Chen, David Estores, Kairui Feng, Hyewon Kim, et al.

    There are limited comparison data throughout the dosing interval for generic versus brand metoprolol extended-release (ER) tablets. We compared the pharmacokinetics (PKs) and pharmacodynamics of brand name versus two generic formulations (drugs 1 and 2) of metoprolol ER tablets with different time to maximum concentration (T-max) in adults with hypertension. Participants were randomized to equal drug doses (50-150 mg/day) administered in one of two sequences (brand-drug1-brand-drug2 or brand-drug2-brand-drug1) and completed 24-h PK, digital heart rate (HR), ambulatory blood pressure (BP), and HR studies after taking each formulation for greater than or equal to 7 days. Metoprolol concentrations were determined by liquid chromatography tandem mass spectrometry, with noncompartmental analysis performed to obtain PK parameters in Phoenix WinNonlin. Heart rate variability (HRV) low-to-high frequency ratio was determined per quartile over the 24-h period. Thirty-six participants completed studies with the brand name and at least one generic product. Among 30 participants on the 50 mg dose, the primary PK end points of area under the concentration-time curve and C-max were similar between products; T-max was 6.1 +/- 3.6 for the brand versus 3.5 +/- 4.9 for drug 1 (p = 0.019) and 9.6 +/- 3.2 for drug 2 (p < 0.001). Among all 36 participants, 24-h BPs and HRs were similar between products. Mean 24-h HRV low-to-high ratio was also similar for drug 1 (2.04 +/- 1.35), drug 2 (1.86 +/- 1.35), and brand (2.04 +/- 1.77), but was more sustained over time for the brand versus drug 1 (drug x quartile interaction p = 0.017). Differences in T-max between metoprolol ER products following repeated doses may have implications for drug effects on autonomic balance over the dosing interval.


  • Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics

    by Meghan J. Arwood, Caitrin W. McDonough, Larisa H. Cavallari, Amanda R. Elsey, Reginald F. Frye, Yan Gong, Taimour Langaee, Julie A. Johnson, Kristin Wiisanen


  • Intensive Care Unit Delirium in Surgical Patients Is Associated with Upregulation in Tryptophan Metabolism

    by Stacy A. Voils, Bethany R. Shoulders, Sonal Singh, Laurence M. Solberg, Timothy J. Garrett, Reginald F. Frye

    Introduction: In intensive care unit (ICU) patients, delirium is frequent, occurs early in ICU admission, and is associated with poor outcomes. Risk models based on clinical factors have shown variable performance in terms of predictive ability. Identification of a candidate biomarker that associates with delirium may lead to a better understanding of disease mechanism, validation biomarker studies, and the ability to develop targeted interventions for prevention and treatment of delirium. This study analyzed metabolite concentrations early in the course of ICU admission to assess the association with delirium onset.Methods: Within 24 hours of ICU admission, blood samples for global and targeted metabolomics analyses in adult surgical ICU patients were collected prospectively. Metabolites were determined using mass spectrometry/ultra‐high‐pressure liquid chromatography and analyzed in patients with delirium and a group of controls matched on age, sex, and admission Sequential Organ Function Assessment (SOFA) score.Results: Patients in the study (65 per group) were a mean age of 59 years, had a median SOFA score of 6, and were most commonly admitted to the ICU following major trauma. In the delirium group, median onset of delirium was 3 (interquartile range 1–6) days, and the most common delirium subtype was mixed (56%). Kynurenic acid was significantly increased, and tryptophan concentration was significantly decreased in the delirium group (p=0.04). The ratio of kynurenine‐to‐tryptophan concentration was significantly higher in the delirium group (p=0.005).Conclusions: Evidence of upregulation was found in the tryptophan metabolic pathway in delirious patients because tryptophan concentrations were lower, tryptophan metabolites were higher, and the kynurenine‐to‐tryptophan ratio was increased. These findings suggest a role of increased inflammation and accumulation of neurotoxic metabolites in the pathogenesis of ICU delirium. Future studies should target this pathway to validate metabolites in the tryptophan pathway as risk biomarkers in patients with ICU delirium.


  • Open Access

    Effect of pterostilbene on in vitro drug metabolizing enzyme activity

    by Ahmed A. Albassam, Reginald F. Frye

    Pterostilbene is a natural polyphenol compound found in small berries that is related to resveratrol, but has better bioavailability and a longer half-life. The purpose of this study was to assess the potential inhibitory effect of pterostilbene on in vitro drug metabolism. The effect of pterostilbene on cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzyme activities were studied using the enzyme-selective substrates amodiaquine (CYP2C8), midazolam (CYP3A4), estradiol (UGT1A1), serotonin (UGT1A6) and mycophenolic acid (UGT1A8/9/10). The IC50 value was used to express the strength of inhibition. Further, a volume per dose index (VDI) was used to estimate the potential for in vivo interactions. Pterostilbene significantly inhibited CYP2C8 and UGT1A6 activities. The IC50 (mean ± SE) values for CYP2C8 and UGT1A6 inhibition were 3.0 ± 0.4 µM and 15.1 ± 2.8 µM, respectively; the VDI exceeded the predefined threshold of 5 L/dose for both CYP2C8 and UGT1A6, suggesting a potential for interaction in vivo. Pterostilbene did not inhibit the metabolism of the other enzyme-selective substrates. The results of this study indicate that pterostilbene inhibits CYP2C8 and UTG1A6 activity in vitro and may inhibit metabolism by these enzymes in vivo. Clinical studies are warranted to evaluate the in vivo relevance of these interactions.


  • Open Access

    A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis

    by Marina Kawaguchi-Suzuki, Kenneth Cusi, Fernando Bril, Yan Gong, Taimour Langaee, Reginald F. Frye

    Pioglitazone is used effectively to treat non-alcoholic steatohepatitis (NASH), but there is marked variability in response. This study examined whether genetic variation contributes to pioglitazone response variability in patients with NASH. This genetic substudy includes 55 participants of a randomized controlled trial designed to determine the efficacy of long-term pioglitazone treatment in patients with NASH. The primary outcome of the clinical trial was defined as ≥2-point reduction in the non-alcoholic fatty liver disease activity score (NAS). In this substudy, single nucleotide polymorphisms (SNPs) in putative candidate genes were tested for association with primary and secondary outcomes. A genetic response score was constructed based on the sum of response alleles for selected genes. The genetic response score was significantly associated with achievement of the primary outcome (odds ratio 1.74; 95% CI 1.27–2.54; p = 0.0015). ADORA1 rs903361 associated with resolution of NASH (p = 0.0005) and change in the ballooning score among Caucasian and Hispanic patients (p = 0.0005). LPL rs10099160 was significantly associated with change in ALT (p = 0.0005). The CYP2C8∗3 allele, which confers faster pioglitazone clearance in allele carriers, was associated with change in fibrosis score (p = 0.026). This study identified key genetic factors that explain some of the inter-individual variability in response to pioglitazone among patients with NASH.


  • Open Access

    Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics

    by Mohamed H. Shahin, Yan Gong, Reginald F. Frye, Daniel M. Rotroff, Amber L. Beitelshees, Rebecca A. Baillie, Arlene B. Chapman, John G. Gums, Stephen T. Turner, Eric Boerwinkle, et al.

    Background: Although hydrochlorothiazide ( HCTZ ) is a well‐established first‐line antihypertensive in the United States, P =5.8E‐05). Testing 78 variants, within 14 genes involved in the sphingolipid metabolic canonical pathway, with the BP response to HCTZ identified variant rs6078905, within the SPTLC 3 gene, as a novel biomarker significantly associated with the BP response to HCTZ in whites (n=228). We found that rs6078905 C‐allele carriers had a better BP response to HCTZ versus noncarriers (∆ SBP /∆ DBP : −11.4/−6.9 versus −6.8/−3.5 mm Hg; ∆ SBP P =6.7E‐04; ∆ DBP P =4.8E‐04). Additionally, in blacks (n=148), we found genetic signals in the SPTLC 3 genomic region significantly associated with the BP response to HCTZ ( P r =−0.42; P =7E‐03) and SBP ‐response ( r =−0.36; P =2E‐02). Conclusions: This study provides insight into potential pharmacometabolomic and genetic mechanisms underlying HCTZ BP response and suggests that SPTLC 3 is a potential determinant of the BP response to HCTZ . Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00246519.